A Computational Method for Unveiling the Target Promiscuity of Pharmacologically Active Compounds.

Drug discovery is governed by the desire to find ligands with defined modes of action. It has been realized that even designated selective drugs may have more macromolecular targets than is commonly thought. Consequently, it will be mandatory to consider multitarget activity for the design of future medicines. Computational models assist medicinal chemists in this effort by helping to eliminate unsuitable lead structures and spot undesired drug effects early in the discovery process. Here, we present a straightforward computational method to find previously unknown targets of pharmacologically active compounds. Validation experiments revealed hitherto unknown targets of the natural product resveratrol and the nonsteroidal anti-inflammatory drug celecoxib. The obtained results advocate machine learning for polypharmacology-based molecular design, drug re-purposing, and the "de-orphaning" of phenotypic drug effects.

[1]  G. Schneider,et al.  Revealing the Macromolecular Targets of Fragment-Like Natural Products. , 2015, Angewandte Chemie.

[2]  S. Kulp,et al.  3-Phosphoinositide-Dependent Protein Kinase-1/Akt Signaling Represents a Major Cyclooxygenase-2-Independent Target for Celecoxib in Prostate Cancer Cells , 2004, Cancer Research.

[3]  George Papadatos,et al.  The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..

[4]  S. Arico,et al.  Celecoxib Induces Apoptosis by Inhibiting 3-Phosphoinositide-dependent Protein Kinase-1 Activity in the Human Colon Cancer HT-29 Cell Line* , 2002, The Journal of Biological Chemistry.

[5]  M. Fielden,et al.  Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. , 2005, Journal of biotechnology.

[6]  S. Shi,et al.  Clinical use and pharmacological properties of selective COX-2 inhibitors , 2008, European Journal of Clinical Pharmacology.

[7]  Muzeeb Syed,et al.  Mitochondrial toxicity of selective COX-2 inhibitors via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria. , 2016, Toxicology in vitro : an international journal published in association with BIBRA.

[8]  Shuqin Zhang,et al.  Drug-target interaction prediction by integrating multiview network data , 2017, Comput. Biol. Chem..

[9]  S. O. Mueller,et al.  Phytoestrogens and Their Human Metabolites Show Distinct Agonistic and Antagonistic Properties on Estrogen Receptor α (ERα)and ERβ in Human Cells , 2004 .

[10]  T. Schnitzer,et al.  Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials , 2013, BDJ.

[11]  Petra Schneider,et al.  Identifying the macromolecular targets of de novo-designed chemical entities through self-organizing map consensus , 2014, Proceedings of the National Academy of Sciences.

[12]  Lengchen Hou,et al.  Does celecoxib improve the efficacy of chemotherapy for advanced non-small cell lung cancer? , 2016, British journal of clinical pharmacology.

[13]  R. Frazzi,et al.  Cellular and Molecular Targets of Resveratrol on Lymphoma and Leukemia Cells , 2017, Molecules.

[14]  Byung-Hwan Lee,et al.  Resveratrol Inhibits GABAC ρ Receptor-Mediated Ion Currents Expressed in Xenopus Oocytes , 2013, The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology.

[15]  Lydia Siragusa,et al.  BioGPS: The Music for the Chemo‐ and Bioinformatics Walzer , 2014, Molecular informatics.

[16]  G. Klebe,et al.  Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. , 2004, Journal of medicinal chemistry.

[17]  F. Cianchi,et al.  Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells , 2006, Molecular Cancer Therapeutics.

[18]  M. Miksits,et al.  Expression of sulfotransferases and sulfatases in human breast cancer: impact on resveratrol metabolism. , 2010, Cancer letters.

[19]  Ajay N. Jain,et al.  Robust ligand-based modeling of the biological targets of known drugs. , 2006, Journal of medicinal chemistry.

[20]  J. Gierse,et al.  Kinetic basis for selective inhibition of cyclo-oxygenases. , 1999, The Biochemical journal.

[21]  Y. Fernández-Marrero,et al.  Survival control of malignant lymphocytes by anti-apoptotic MCL-1 , 2016, Leukemia.

[22]  L. Pirola,et al.  Resveratrol: One molecule, many targets , 2008, IUBMB life.

[23]  P. Ling,et al.  Biosignaling of mammalian Ste20-related kinases. , 2008, Cellular signalling.

[24]  S. Saini,et al.  The Cox-2-Specific Inhibitor Celecoxib Inhibits Adenylyl Cyclase , 2003, Inflammation.

[25]  P. Greengard,et al.  Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  G. Schneider,et al.  Review : Macromolecular target prediction by self-organizing feature maps , 2016 .

[27]  Steven V. Fox,et al.  Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators , 2013, Front. Neurosci..

[28]  A. Drost,et al.  The G protein-coupled receptor CysLT1 mediates chemokine-like effects and prolongs survival in chronic lymphocytic leukemia , 2012, Leukemia & lymphoma.

[29]  A. Hsu,et al.  The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. , 2002, The Biochemical journal.

[30]  B. Viollet,et al.  Resveratrol Inhibits Cardiac Hypertrophy via AMP-activated Protein Kinase and Akt* , 2008, Journal of Biological Chemistry.

[31]  C. De Monte,et al.  Dual Cyclooxygenase and Carbonic Anhydrase Inhibition by Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Cancer. , 2015, Current medicinal chemistry.

[32]  A. Schönthal,et al.  Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy , 2007, British Journal of Cancer.

[33]  P. Groundwater,et al.  The Differential Effects of Resveratrol and trans-ε-Viniferin on the GABA-Induced Current in GABAA Receptor Subtypes Expressed in Xenopus Laevis Oocytes. , 2015, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[34]  Zheng Yin,et al.  Improving chemical similarity ensemble approach in target prediction , 2016, Journal of Cheminformatics.

[35]  Gisbert Schneider,et al.  Multi-space classification for predicting GPCR-ligands , 2005, Molecular Diversity.

[36]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[37]  Gustavo Henrique Goulart Trossini,et al.  Use of machine learning approaches for novel drug discovery , 2016, Expert opinion on drug discovery.

[38]  Sanghyun Cho,et al.  Cardiovascular Protective Effects and Clinical Applications of Resveratrol. , 2017, Journal of medicinal food.

[39]  Zhong Chen,et al.  Design, synthesis, biological evaluation and molecular modeling of dihydropyrazole sulfonamide derivatives as potential COX-1/COX-2 inhibitors. , 2015, Bioorganic & medicinal chemistry letters.

[40]  Irina I Ignatova,et al.  Inhibition of hERG Potassium Channels by Celecoxib and Its Mechanism , 2011, PloS one.

[41]  A. Hsu,et al.  The Cyclooxygenase-2 Inhibitor Celecoxib Induces Apoptosis by Blocking Akt Activation in Human Prostate Cancer Cells Independently of Bcl-2* , 2000, The Journal of Biological Chemistry.

[42]  F. Sarubbo,et al.  Improving effect of chronic resveratrol treatment on central monoamine synthesis and cognition in aged rats , 2015, AGE.

[43]  Theodora Katsila,et al.  Computational approaches in target identification and drug discovery , 2016, Computational and structural biotechnology journal.

[44]  J. Nwachukwu,et al.  Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network , 2014, eLife.

[45]  Lionel Colliandre,et al.  e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design , 2012, Bioinform..

[46]  J. Bajorath Computational approaches in chemogenomics and chemical biology: current and future impact on drug discovery , 2008, Expert opinion on drug discovery.

[47]  B. Thompson,et al.  MST kinases in development and disease , 2015, The Journal of cell biology.

[48]  K. Pallauf,et al.  Resveratrol and Lifespan in Model Organisms. , 2016, Current medicinal chemistry.

[49]  P Schneider,et al.  De-orphaning the marine natural product (±)-marinopyrrole A by computational target prediction and biochemical validation. , 2017, Chemical communications.

[50]  Hao Ding,et al.  Similarity-based machine learning methods for predicting drug-target interactions: a brief review , 2014, Briefings Bioinform..

[51]  A. Nishi,et al.  Acute effects of resveratrol to enhance cocaine-induced dopamine neurotransmission in the striatum , 2013, Neuroscience Letters.